17P DELETION P53 (MM, CLL) / HEPARIN BLOOD

image not found

NABL Cap Accredited 
The 17p Deletion P53 (MM, CLL) Test using heparinized blood at Metropolis Healthcare identifies the loss of the P53 gene on chromosome 17, commonly associated with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). This chromosomal deletion is linked to aggressive disease behavior and poor prognosis. Detecting the 17p deletion helps doctors make informed treatment and management decisions. The test provides insights into disease progression and therapy response. It supports personalized care and monitoring of hematologic malignancies.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 5,195.00

Sample Type: HEPARIN BLOOD

Fasting Not Required


Booking Procedure:
  1. Technician from Metropolis will be assigned for a free home sample collection after booking confirmation.
  2. Sample will be collected by our technician at your address at given slot.
  3. You will get a payment link in 2 hours. You can make the payment online or pay cash to the technician.
  4. Soft copy reports will be sent to your email address within 24 to 48 hours.

Notes: #0031

Frequently Asked Questions (FAQ's):

1. What is the 17p Deletion P53 (MM, CLL) Test using heparinized blood?
This test detects the deletion of the P53 gene on chromosome 17 in patients with multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) using a heparin-treated blood sample.

2. Why is this test important?
It helps evaluate disease aggressiveness, prognosis, and supports personalized treatment decisions in patients with MM or CLL.

3. Who should undergo this test?
Patients diagnosed with or suspected of having MM or CLL may be advised to take this test to assess genetic abnormalities.

4. How is the test performed?
At Metropolis Healthcare, a heparinized blood sample is collected and analyzed using advanced cytogenetic and molecular diagnostic techniques.

5. What do the results indicate?
A detected 17p deletion suggests P53 gene loss, which is associated with poor prognosis and therapy resistance, guiding treatment strategies.

6. Are there any risks associated with the test?
The test is safe, with minimal risk related to blood sample collection.

7. Why choose Metropolis Healthcare for this test?
Metropolis Healthcare offers advanced genetic testing with expert analysis and modern technology, ensuring accurate results for effective management of MM and CLL.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab